Overview

Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Status:
Recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborators:

Children's Oncology Group
Innovative Therapies For Children with Cancer Consortium

Treatments:

Cytarabine
Daunorubicin
Etoposide
Etoposide phosphate
Fludarabine
Fludarabine phosphate
Vidarabine